TW200800996A - Heterobicyclic pyrazole compounds and methods of use - Google Patents

Heterobicyclic pyrazole compounds and methods of use

Info

Publication number: TW200800996A
Authority: TW; Taiwan
Prior art keywords: methods; compounds; pyrazole compounds; tautomers; solvates
Prior art date: 2006-03-07

Application number

TW096107890A

Other languages

English (en)

Inventor

James F Blake

Steven Boyd

Meese Jason De

Kin Chiu Fong

John J Gaudino

Tomas Kaplan

Allison L Marlow

Jeongbeob Seo

Allen A Thomas

Hongqi Tian

Frederick Cohen

Wendy B Young

Original Assignee

Array Biopharma Inc

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-07

Filing date

2007-03-07

Publication date

2008-01-01

2007-03-07 Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc

2008-01-01 Publication of TW200800996A publication Critical patent/TW200800996A/zh

Links

238000000034 method Methods 0.000 title abstract 2
-1 Heterobicyclic pyrazole compounds Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000012453 solvate Substances 0.000 abstract 2
238000003745 diagnosis Methods 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
238000011065 in-situ storage Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
210000004962 mammalian cell Anatomy 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
102000027426 receptor tyrosine kinases Human genes 0.000 abstract 1
108091008598 receptor tyrosine kinases Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Dermatology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)

TW096107890A 2006-03-07 2007-03-07 Heterobicyclic pyrazole compounds and methods of use TW200800996A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US77980506P	2006-03-07	2006-03-07
US87483206P	2006-12-14	2006-12-14

Publications (1)

Publication Number	Publication Date
TW200800996A true TW200800996A (en)	2008-01-01

Family

ID=38475465

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW096107890A TW200800996A (en)	2006-03-07	2007-03-07	Heterobicyclic pyrazole compounds and methods of use

Country Status (20)

Country	Link
US (2)	US7723330B2 (zh)
EP (1)	EP2001880A2 (zh)
JP (1)	JP2009529047A (zh)
KR (1)	KR20080110783A (zh)
AR (1)	AR059887A1 (zh)
AU (1)	AU2007224020A1 (zh)
BR (1)	BRPI0708615A2 (zh)
CA (1)	CA2645137A1 (zh)
CL (1)	CL2007000601A1 (zh)
CO (1)	CO6140061A2 (zh)
CR (1)	CR10338A (zh)
EC (1)	ECSP088791A (zh)
IL (1)	IL193587A0 (zh)
MA (1)	MA31339B1 (zh)
MX (1)	MX2008011220A (zh)
NO (1)	NO20084183L (zh)
RU (1)	RU2008139599A (zh)
TW (1)	TW200800996A (zh)
WO (1)	WO2007103308A2 (zh)
ZA (1)	ZA200807632B (zh)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003201573B2 (en) *	2002-01-22	2009-02-26	Biomatera Inc.	Method of drying biodegradable polymers
WO2006068760A2 (en)	2004-11-19	2006-06-29	The Regents Of The University Of California	Anti-inflammatory pyrazolopyrimidines
KR20080110783A (ko) *	2006-03-07	2008-12-19	어레이 바이오파마 인크.	헤테로바이시클릭 피라졸 화합물 및 사용 방법
KR20130087054A (ko)	2006-04-04	2013-08-05	더 리젠트스 오브 더 유니이버시티 오브 캘리포니아	키나제 길항물질
EP2032538A2 (en) *	2006-06-08	2009-03-11	Array Biopharma, Inc.	Quinoline compounds and methods of use
DE602007013573D1 (de) *	2006-08-16	2011-05-12	Hoffmann La Roche	Nicht-nukleosidische reverse-transkriptase-hemmer
US7776857B2 (en) *	2007-04-05	2010-08-17	Amgen Inc.	Aurora kinase modulators and method of use
JP5656634B2 (ja)	2007-08-29	2015-01-21	メチルジーンインコーポレイテッド	タンパク質チロシンキナーゼ活性の阻害剤
WO2009046448A1 (en)	2007-10-04	2009-04-09	Intellikine, Inc.	Chemical entities and therapeutic uses thereof
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MY172151A (en)	2008-01-04	2019-11-14	Intellikine Llc	Certain chemical entities, compositions and methods
WO2009089352A1 (en)	2008-01-08	2009-07-16	Array Biopharma Inc.	Pyrrolopyridines as kinase inhibitors
CN101965347B (zh)	2008-01-09	2013-01-02	阵列生物制药公司	作为激酶抑制剂的吡唑并吡啶
WO2009094427A1 (en)	2008-01-23	2009-07-30	Bristol-Myers Squibb Company	4-pyridinone compounds and their use for cancer
WO2009095752A1 (en) *	2008-01-29	2009-08-06	Glenmark Pharmaceuticals, S.A.	Fused pyrazole derivatives as cannabinoid receptor modulators
BRPI0906099A2 (pt) *	2008-03-06	2015-07-21	Genentech Inc	"método de tratamento do câncer em um indivíduo"
WO2009114874A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Kinase inhibitors and methods of use
CA2727204C (en) *	2008-06-09	2016-02-02	Bayer Schering Pharma Aktiengesellschaft	Substituted 4-(indazolyl)-1,4-dihydropyridines and methods of use thereof
WO2009149836A1 (en) *	2008-06-09	2009-12-17	Bayer Schering Pharma Aktiengesellschaft	Annellated 4- (indazolyl) -1,4-dihydropyridine derivatives and methods of use thereof
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
JP5788316B2 (ja)	2008-07-08	2015-09-30	インテリカイン，エルエルシー	キナーゼインヒビターおよび使用方法
TWI365185B (en) *	2008-07-24	2012-06-01	Lilly Co Eli	Amidophenoxyindazoles useful as inhibitors of c-met
CA2738026C (en)	2008-09-22	2017-01-24	Array Biopharma Inc.	Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
JP5731978B2 (ja)	2008-09-26	2015-06-10	インテリカイン，エルエルシー	複素環キナーゼ阻害剤
KR100961410B1 (ko) *	2008-10-14	2010-06-09	(주)네오팜	단백질 키나제 억제제로서 헤테로사이클릭 화합물
RU2011119478A (ru) *	2008-10-14	2012-11-27	Нин Си	Соединения и способы применения
CA2740885C (en)	2008-10-16	2018-04-03	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
EP2725028B1 (en)	2008-10-22	2016-05-25	Array Biopharma, Inc.	Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of TRK kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
KR20110084455A (ko) *	2008-11-13	2011-07-22	엑셀리시스, 인코포레이티드	퀴놀린 유도체를 제조하는 방법
EP2387563B2 (en)	2009-01-16	2022-04-27	Exelixis, Inc.	Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
WO2010129816A2 (en)	2009-05-07	2010-11-11	Intellikine, Inc.	Heterocyclic compounds and uses thereof
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011019780A1 (en) *	2009-08-11	2011-02-17	Bristol-Myers Squibb Company	Azaindazoles as btk kinase modulators and use thereof
EA026693B1 (ru)	2009-08-17	2017-05-31	Интелликайн ЭлЭлСи	Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
US20120232062A1 (en) *	2009-10-20	2012-09-13	Eiger Biopharmaceuticals, Inc.	Azaindazoles to treat flaviviridae virus infection
EP2542240B1 (en) *	2010-03-01	2017-04-05	Novadrug, LLC	Compositions and methods for treating viral diseases
US8569319B2 (en)	2010-04-29	2013-10-29	Deciphera Pharmaceuticals, LLS	Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
JP5832527B2 (ja)	2010-05-20	2015-12-16	アレイバイオファーマ、インコーポレイテッド	Ｔｒｋキナーゼ阻害剤としてのマクロ環化合物
JP5951600B2 (ja)	2010-05-21	2016-07-13	インフィニティーファーマシューティカルズ，インコーポレイテッド	キナーゼ調節のための、化合物、組成物および方法
CA2817577A1 (en)	2010-11-10	2012-05-18	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CA2824197C (en)	2011-01-10	2020-02-25	Michael Martin	Processes for preparing isoquinolinones and solid forms of isoquinolinones
EP2487159A1 (en)	2011-02-11	2012-08-15	MSD Oss B.V.	RorgammaT inhibitors
CN103491962B (zh)	2011-02-23	2016-10-12	因特利凯有限责任公司	激酶抑制剂的组合及其用途
US9133162B2 (en)	2011-02-28	2015-09-15	Sunshine Lake Pharma Co., Ltd.	Substituted quinoline compounds and methods of use
WO2012127472A1 (en) *	2011-03-22	2012-09-27	Mapi Pharma Ltd.	Process and intermediates for the preparation of preladenant and related compounds
AU2012284088B2 (en)	2011-07-19	2015-10-08	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
AU2012284091B2 (en)	2011-07-19	2015-11-12	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
CA2844588A1 (en) *	2011-08-10	2013-02-14	Merck Patent Gmbh	Pyrido-pyrimidine derivatives
AU2012302197B2 (en)	2011-08-29	2016-01-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
AU2012341028C1 (en)	2011-09-02	2017-10-19	Mount Sinai School Of Medicine	Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
MX2014002990A (es)	2011-09-19	2014-05-21	Genentech Inc	Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
RU2501800C2 (ru) *	2012-02-07	2013-12-20	Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет"	2-(6-АРИЛ-4-АРОИЛ-3-МЕТИЛ-1-ФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-5-ИЛ)-2-ОКСО-N-АРИЛАЦЕТАМИДЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014026327A1 (en)	2012-08-15	2014-02-20	Merck Sharp & Dohme Corp.	4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) *	2012-08-15	2014-02-20	Merck Sharp & Dohme Corp.	3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2015003874A (es)	2012-09-26	2015-12-16	Univ California	Modulacion de ire1.
AU2013337717B2 (en)	2012-11-01	2018-10-25	Infinity Pharmaceuticals, Inc.	Treatment of cancers using PI3 kinase isoform modulators
UA111687C2 (uk)	2012-11-08	2016-05-25	Пфайзер Інк.	Гетероароматичні сполуки як ліганди допаміну d1
US9260426B2 (en)	2012-12-14	2016-02-16	Arrien Pharmaceuticals Llc	Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN105209042B (zh)	2013-03-22	2019-03-08	米伦纽姆医药公司	催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
EP3052485B1 (en)	2013-10-04	2021-07-28	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3087070B1 (en) *	2013-12-26	2017-11-08	Ignyta, Inc.	Pyrazolo[1,5-a]pyridine derivatives and methods of their use
EA201691872A1 (ru)	2014-03-19	2017-04-28	Инфинити Фармасьютикалз, Инк.	Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
RU2016141385A (ru)	2014-03-24	2018-04-28	Дженентек, Инк.	Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2016004272A1 (en) *	2014-07-02	2016-01-07	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
AU2015346046B2 (en)	2014-11-16	2020-06-25	Array Biopharma, Inc.	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
CA2975997A1 (en)	2015-02-11	2016-08-18	Merck Sharp & Dohme Corp.	Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
SI3328827T1 (sl)	2015-07-31	2023-11-30	The Johns Hopkins University	Predzdravila glutamin analogov
WO2017048702A1 (en)	2015-09-14	2017-03-23	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
MX2018004364A (es) *	2015-10-09	2018-08-16	Abbvie Sarl	Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
CA3003153A1 (en)	2015-10-26	2017-05-04	Loxo Oncology, Inc.	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
KR20180070697A (ko)	2015-10-27	2018-06-26	머크 샤프 앤드 돔 코포레이션	Ror감마t 저해제로서의 치환된 인다졸 화합물 및 이의 용도
AU2016344118A1 (en)	2015-10-27	2018-05-10	Merck Sharp & Dohme Corp.	Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
EP3368516B1 (en)	2015-10-27	2020-07-15	Merck Sharp & Dohme Corp.	SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
WO2017176751A1 (en)	2016-04-04	2017-10-12	Loxo Oncology, Inc.	Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
LT3800189T (lt) *	2016-05-18	2023-10-10	Loxo Oncology, Inc.	(s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroksipirolidin-1-karboksamido gavimas
MX388576B (es)	2016-06-07	2025-03-20	Jacobio Pharmaceuticals Co Ltd	Derivados heterociclicos novedosos utiles como inhibidores de shp2.
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN109640999A (zh)	2016-06-24	2019-04-16	无限药品股份有限公司	组合疗法
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
AU2018239542C1 (en)	2017-03-23	2021-02-11	Jacobio Pharmaceuticals Co., Ltd.	Novel heterocyclic derivatives useful as SHP2 inhibitors
CN108948002A (zh) *	2017-05-19	2018-12-07	厦门大学	五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
EP3638669A1 (en)	2017-06-13	2020-04-22	Bayer Pharma Aktiengesellschaft	Substituted pyrrolopyridine-derivatives
CA3079060A1 (en)	2017-06-13	2018-12-20	Bayer Pharma Aktiengesellschaft	Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
US20200246347A1 (en)	2017-06-13	2020-08-06	Bayer Pharma Aktiengesellschaft	Substituted Pyrrolopyridine-Derivatives
EP3655406A1 (en)	2017-07-18	2020-05-27	Bayer Pharma Aktiengesellschaft	Substituted pyrrolopyridine-derivatives
WO2019121143A1 (en)	2017-12-20	2019-06-27	Basf Se	Substituted cyclopropyl derivatives
EP3730494B1 (en)	2017-12-22	2023-11-08	Sumitomo Chemical Company, Limited	Heterocyclic compound and harmful arthropod controlling agent containing same
EP3743417A1 (en)	2018-01-26	2020-12-02	Exelixis, Inc.	Compounds for the treatment of kinase-dependent disorders
US11708367B2 (en)	2018-01-26	2023-07-25	Exelixis, Inc.	Compounds for the treatment of kinase-dependent disorders
JP6557436B1 (ja)	2018-03-12	2019-08-07	アッヴィ・インコーポレイテッド	チロシンキナーゼ２媒介性シグナル伝達の阻害剤
UY38349A (es) *	2018-08-30	2020-03-31	Array Biopharma Inc	Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN112839935A (zh)	2018-09-26	2021-05-25	北京加科思新药研发有限公司	可用作shp2抑制剂的新型杂环衍生物
WO2020260871A1 (en) *	2019-06-24	2020-12-30	Benevolentai Bio Limited	New compounds and methods
WO2021020362A1 (ja) *	2019-07-29	2021-02-04	武田薬品工業株式会社	複素環化合物
CA3163338A1 (en) *	2019-12-04	2021-06-10	Arcus Biosciences, Inc.	Inhibitors of hif-2alpha
US20230150956A1 (en) *	2020-02-10	2023-05-18	Stemsynergy Therapeutics, Inc.	Myc inhibitors and uses thereof
CN119365192A (zh) *	2022-01-12	2025-01-24	深圳市原力深湾创新药有限公司	作为hpk1抑制剂的杂芳基化合物及其使用方法
TW202413341A (zh)	2022-09-23	2024-04-01	美商富曼西公司	吡唑醯胺殺昆蟲劑

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
ZW12187A1 (en)	1986-07-03	1989-02-01	Janssen Pharmaceutica Nv	4-(aroylamino)piperidinebutanamide derivatives
AU3262593A (en)	1992-01-11	1993-08-03	Schering Agrochemicals Limited	Biheterocyclic fungicidal compounds
US5252581A (en)	1992-07-20	1993-10-12	Hoechst-Roussel Pharmaceuticals Inc.	Substituted aminothienopyridines, pharmaceutical composition and use
DK0765327T3 (da)	1994-06-16	1999-11-29	Pfizer	Pyrazolo- og pyrrolopyridiner
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
ES2251741T3 (es)	1996-08-23	2006-05-01	Sugen, Inc.	Bibliotecas combinatorias de indolinona y productos afines y metodos para el tratamiento de enfermedades.
ATE291022T1 (de) *	1996-10-02	2005-04-15	Novartis Pharma Gmbh	Pyrimiderivate und verfahren zu ihrer herstellung
DE69837282T2 (de)	1997-12-13	2007-11-08	Bristol-Myers Squibb Co.	VERWENDUNG VON PYRAZOLO Ä 3,4-bÜ PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
GB9906566D0 (en)	1999-03-23	1999-05-19	Zeneca Ltd	Chemical compounds
US6297238B1 (en)	1999-04-06	2001-10-02	Basf Aktiengesellschaft	Therapeutic agents
ATE247657T1 (de) *	1999-09-17	2003-09-15	Basf Ag	Pyrazolopyrimidine als arzneimittel
US6921763B2 (en) *	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
JP2004507455A (ja)	2000-04-25	2004-03-11	ブリストル−マイヤーズ　スクイブ　カンパニー	サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途
AU2001264313A1 (en)	2000-06-20	2002-01-02	Japan Tobacco Inc.	Pyrazolopyridine compounds and use thereof as drugs
JP2002020386A (ja) *	2000-07-07	2002-01-23	Ono Pharmaceut Co Ltd	ピラゾロピリジン誘導体
US6599902B2 (en)	2001-05-30	2003-07-29	Sugen, Inc.	5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
AR036040A1 (es)	2001-06-12	2004-08-04	Upjohn Co	Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
EP2088141A3 (en)	2001-06-22	2009-11-18	Kirin Pharma Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
CA2460075A1 (en)	2001-09-12	2003-03-20	Donn Gregory Wishka	Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
JP2005516023A (ja)	2001-12-19	2005-06-02	スミスクラインビーチャムコーポレーション	プロテインチロシンキナーゼ阻害剤としてのチエノピリミジン化合物
AU2003239302A1 (en)	2002-01-29	2003-09-02	Glaxo Group Limited	Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
JP4445753B2 (ja)	2002-01-29	2010-04-07	グラクソグループリミテッド	アミノピペリジン誘導体
US6790852B2 (en)	2002-04-18	2004-09-14	Hoffmann-La Roche Inc.	2-(2,6-dichlorophenyl)-diarylimidazoles
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
JP4754821B2 (ja)	2002-06-20	2011-08-24	プロキシマゲン・リミテッド	肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
TW200409637A (en)	2002-06-26	2004-06-16	Glaxo Group Ltd	Compounds
AU2003257145B2 (en)	2002-08-02	2008-11-13	Merck Sharp & Dohme Corp.	Substituted furo (2,3-b) pyridine derivatives
MXPA05001688A (es) *	2002-08-12	2005-04-19	Sugen Inc	3-pirrolil-piridopirazoles y 3-pirrolil-indazoles como inhibidores de cinasa novedosos.
GB0230045D0 (en)	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
DK1539753T3 (da)	2002-09-16	2010-01-04	Glaxo Group Ltd	Pyrazolo(3,4B9pyridin-forbindelser og deres anvendelse som phosphodiesterase-inhibitorer
JP2006503864A (ja)	2002-10-01	2006-02-02	ジヨンソン・アンド・ジヨンソン・フアーマシユーチカル・リサーチ・アンド・デベロツプメント・インコーポレーテツド	タンパク質チロシンキナーゼ阻害剤としての４，６−ジアミノ置換−２−［オキシ又はアミノキシ］−［１，３，５］トリアジン
AR042486A1 (es)	2002-12-18	2005-06-22	Glaxo Group Ltd	Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
MEP52808A (en)	2003-02-26	2011-05-10	Sugen Inc	Aminoheteroaryl compounds as protein kinase inhibitors
EP1615906A1 (en)	2003-04-03	2006-01-18	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
US7037909B2 (en)	2003-07-02	2006-05-02	Sugen, Inc.	Tetracyclic compounds as c-Met inhibitors
BRPI0412040A (pt)	2003-07-02	2006-09-05	Sugen Inc	hidrazidas de indolinona como inibidores de c-met
US7122548B2 (en)	2003-07-02	2006-10-17	Sugen, Inc.	Triazolotriazine compounds and uses thereof
AR045342A1 (es)	2003-08-15	2005-10-26	Merck & Co Inc	Inhibidores de quinesina mitotica
PL2210607T3 (pl)	2003-09-26	2012-01-31	Exelixis Inc	N-[3-fluoro-4-({6-(metyloksy)-7-[(3-morfolin-4-ylopropylo)oksy]chinolin-4-ylo} oxy)fenylo]-N'-(4-fluorofenylo)cyklopropano-1,1-dikarboksamid do leczenia raka
AU2004299277A1 (en)	2003-12-19	2005-06-30	Glaxo Group Limited	Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
WO2005061476A2 (en)	2003-12-22	2005-07-07	Basilea Pharmaceutica Ag	Aroylfuranes and aroylthiophenes
WO2005070891A2 (en)	2004-01-23	2005-08-04	Amgen Inc	Compounds and methods of use
KR100843526B1 (ko)	2004-02-27	2008-07-03	에프. 호프만-라 로슈 아게	피라졸의 접합 유도체
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en)	2004-06-09	2005-12-22	Pfizer Inc.	Ether-linked heteroaryl compounds
US20050288290A1 (en)	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
WO2006014325A2 (en) *	2004-07-02	2006-02-09	Exelixis, Inc.	C-met modulators and method of use
WO2006060318A2 (en)	2004-11-30	2006-06-08	Amgen Inc.	Quinolines and quinazoline analogs and their use as medicaments for treating cancer
CA2603876A1 (en)	2005-04-19	2006-10-26	Merck & Co., Inc.	N-alkyl-azacycloalkyl nmda/nr2b antagonists
US7470693B2 (en)	2005-04-21	2008-12-30	Bristol-Myers Squibb Company	Oxalamide derivatives as kinase inhibitors
JO2787B1 (en)	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
JP5148499B2 (ja)	2005-05-20	2013-02-20	メチルジーンインコーポレイテッド	Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤
FR2889526B1 (fr)	2005-08-04	2012-02-17	Aventis Pharma Sa	7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US7732613B2 (en)	2005-09-14	2010-06-08	Bristol-Myers Squibb Company	Met kinase inhibitors
US7880004B2 (en)	2005-09-15	2011-02-01	Bristol-Myers Squibb Company	Met kinase inhibitors
US7547782B2 (en)	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
KR20080110783A (ko) *	2006-03-07	2008-12-19	어레이 바이오파마 인크.	헤테로바이시클릭 피라졸 화합물 및 사용 방법
AR060061A1 (es)	2006-03-22	2008-05-21	Methylgene Inc	Inhibidores de la actividad de la proteina tirosina quinasa
EA018670B9 (ru) *	2007-03-14	2014-01-30	Ранбакси Лабораториз Лимитед	Производные пиразоло[3,4-в]пиридина в качестве ингибиторов фосфодиэстеразы
BRPI0821349A2 (pt) *	2007-12-21	2019-09-24	Hoffmann La Roche	compostos antivirais heterocíclicos

2007
- 2007-03-06 KR KR1020087024415A patent/KR20080110783A/ko not_active Withdrawn
- 2007-03-06 EP EP07752297A patent/EP2001880A2/en not_active Withdrawn
- 2007-03-06 RU RU2008139599/04A patent/RU2008139599A/ru not_active Application Discontinuation
- 2007-03-06 AU AU2007224020A patent/AU2007224020A1/en not_active Abandoned
- 2007-03-06 CA CA002645137A patent/CA2645137A1/en not_active Abandoned
- 2007-03-06 BR BRPI0708615-6A patent/BRPI0708615A2/pt not_active Application Discontinuation
- 2007-03-06 US US11/714,342 patent/US7723330B2/en not_active Expired - Fee Related
- 2007-03-06 MX MX2008011220A patent/MX2008011220A/es not_active Application Discontinuation
- 2007-03-06 JP JP2008558335A patent/JP2009529047A/ja active Pending
- 2007-03-06 WO PCT/US2007/005583 patent/WO2007103308A2/en active Application Filing
- 2007-03-07 TW TW096107890A patent/TW200800996A/zh unknown
- 2007-03-07 AR ARP070100948A patent/AR059887A1/es unknown
- 2007-03-07 CL CL2007000601A patent/CL2007000601A1/es unknown
2008
- 2008-08-21 IL IL193587A patent/IL193587A0/en unknown
- 2008-09-04 ZA ZA2008/07632A patent/ZA200807632B/en unknown
- 2008-09-19 MA MA31254A patent/MA31339B1/fr unknown
- 2008-09-30 CO CO08104090A patent/CO6140061A2/es unknown
- 2008-10-02 CR CR10338A patent/CR10338A/es unknown
- 2008-10-06 EC EC2008008791A patent/ECSP088791A/es unknown
- 2008-10-06 NO NO20084183A patent/NO20084183L/no not_active Application Discontinuation
2010
- 2010-01-26 US US12/693,975 patent/US20100256356A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7723330B2 (en)	2010-05-25
MA31339B1 (fr)	2010-05-03
AR059887A1 (es)	2008-05-07
CO6140061A2 (es)	2010-03-19
NO20084183L (no)	2008-11-24
CR10338A (es)	2008-10-31
JP2009529047A (ja)	2009-08-13
AU2007224020A1 (en)	2007-09-13
CL2007000601A1 (es)	2008-01-25
US20070238726A1 (en)	2007-10-11
IL193587A0 (en)	2009-08-03
WO2007103308A3 (en)	2008-02-07
ZA200807632B (en)	2011-04-28
KR20080110783A (ko)	2008-12-19
CA2645137A1 (en)	2007-09-13
EP2001880A2 (en)	2008-12-17
WO2007103308A2 (en)	2007-09-13
ECSP088791A (es)	2008-11-27
US20100256356A1 (en)	2010-10-07
RU2008139599A (ru)	2010-04-20
BRPI0708615A2 (pt)	2011-06-07
MX2008011220A (es)	2008-09-11

Publication	Publication Date	Title
TW200800996A (en)	2008-01-01	Heterobicyclic pyrazole compounds and methods of use
WO2007146824A3 (en)	2008-04-10	Quinoline compounds and methods of use
TW200801012A (en)	2008-01-01	Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2007127175A3 (en)	2007-12-27	Pharmaceutical compounds
PH12013501779B1 (en)	2019-02-13	Pyrrolopyridines as kinase inhibitors
WO2007027855A3 (en)	2007-05-03	Raf inhibitor compounds and methods of use thereof
WO2006125101A3 (en)	2007-03-29	Raf inhibitor compounds and methods of use thereof
MX2010010659A (es)	2010-10-26	Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos.
PH12019501792A1 (en)	2021-03-22	Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
WO2008063202A3 (en)	2009-01-22	Heterobicyclic thiophene compounds for the treatment of cancer
WO2009111278A3 (en)	2010-07-15	Raf inhibitor compounds and methods of use thereof
MX2010002543A (es)	2010-03-29	Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
MX2011012520A (es)	2011-12-12	Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
TW200639163A (en)	2006-11-16	RAF inhibitor compounds and methods
PH12012500608A1 (en)	2017-08-09	Benzoxepin pi3k inhibitor compounds and methods of use
SG178899A1 (en)	2012-04-27	Raf inhibitor compounds and methods of use thereof
WO2008028141A3 (en)	2008-04-10	Raf inhibitor compounds and methods of use thereof
MA32272B1 (fr)	2011-05-02	Inhibiteurs de raf de pyrazole [3,4-b]pyridine
MX2011009167A (es)	2011-09-15	Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapeuticos para el tratamiento contra neoplasia hemotopoyeticas malignas.
SG178900A1 (en)	2012-04-27	Raf inhibitor compounds and methods of use thereof